Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 15 Aug 2019 According to a Hemispherx Biopharma media release, An interim report was received and a manuscript is being drafted on the biological and clinical outcomes from the Phase 1 portion of the trial.
- 15 Aug 2019 According to a Hemispherx Biopharma media release, Eleven patients in the Phase 1 portion have been enrolled; 10 have completed treatment and one is undergoing treatment and evaluation.
- 12 Jun 2019 According to a Hemispherx Biopharma media release, first patient has been treated in this study at the University of Pittsburgh Medical Center (UPMC).